Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ThredUp Inc (TDUP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ThredUp Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.79 (market cap $4.49B), while ThredUp Inc trades at $6.35 (market cap $882.64M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 5.1× ThredUp Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | TDUP | |
|---|---|---|
Market Cap | $4.49B | $882.64M |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $12.08 |
52-Week Low | $20.06 | $3.11 |
Enterprise Value | $3.69B | $885.37M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
TDUP trades at $6.84, down 2.7% today, with a consensus price target of $6.90. The stock shows bullish technical signals from moving averages, though oscillators are neutral. Recent Q1 2026 results met EPS expectations with record active buyers and 15% revenue growth. The company maintains a high gross margin of 79.4% but continues to report net losses, with improving cash flow from operations turning positive in 2025.
Investment outlook remains cautiously optimistic given analyst consensus (57% buy ratings) and recent business initiatives including AI integration and marketplace expansion. Key risks include persistent unprofitability and competitive pressures in resale markets. The stock presents potential for growth if margin improvements continue, but requires monitoring of earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
